At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 848 enrolled
Drug / intervention
Ceftaroline +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Multicentre, Randomised, Double-Blind, Comparative Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia
In Brief
A Phase 3 clinical trial evaluating Ceftaroline and Ceftriaxone for Community-Acquired Bacterial Pneumonia and Lung Infection of Individual Not Recently Hospitalized. Completed, enrolled 848 participants across 43 sites in 5 countries.
Detailed Summary
This purpose of this study is to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCommunity-Acquired Bacterial Pneumonia, Lung Infection of Individual Not Recently Hospitalized
CountriesChina, India, South Korea, Taiwan, Vietnam
CollaboratorsForest Laboratories
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 2011
Enrollment StartDec 2011
Primary CompletionMay 2013
TodayJul 2026
First PostedJun 13, 2011
Enrollment StartDec 1, 2011
Primary CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 15.1 years ago
Interventions
Ceftarolinedrug
Two consecutive infusions q12h for 5 to 7 days
Ceftriaxonedrug
One dose infusion followed by IV saline placebo infused q24h for 5 to 7 days plus two consecutive saline placebo infusion q24h.